SARS-CoV-2 peptides bind to NKG2D and increase NK cell activity

Cited 24 time in scopus
Metadata Downloads

Full metadata record

DC FieldValueLanguage
dc.contributor.authorHanna Kim-
dc.contributor.authorByun Jae Eun-
dc.contributor.authorSuk Ran Yoon-
dc.contributor.authorH Koohy-
dc.contributor.authorHaiyoung Jung-
dc.contributor.authorIn Pyo Choi-
dc.date.accessioned2021-11-11T15:30:21Z-
dc.date.available2021-11-11T15:30:21Z-
dc.date.issued2022-
dc.identifier.issn0008-8749-
dc.identifier.urihttps://oak.kribb.re.kr/handle/201005/24988-
dc.description.abstractImmune dysregulation is commonly observed in patients with coronavirus disease 2019 (COVID-19). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces severe lung inflammation and innate immune cell dysregulation. However, the precise interaction between SARS-CoV-2 and the innate immune system is currently unknown. To understand the interaction between SARS-CoV-2 and natural killer (NK) cells, several SARS-CoV-2 S protein peptides capable of binding to the NKG2D receptor were screened by in silico analysis. Among them, two peptides, cov1 and cov2, bound to NK cells and NKG2D receptors. These cov peptides increased NK cytotoxicity toward lung cancer cells, stimulated interferon gamma (IFN-γ) production by NK cells, and likely mediated these responses through the phosphorylation of Vav1, a key downstream-signaling molecule of NKG2D and NK activation genes. The direct interaction between SARS-CoV-2 and NK cells is a novel finding, and modulation of this interaction has potential clinical application as a therapeutic target for COVID-19.-
dc.publisherElsevier-
dc.titleSARS-CoV-2 peptides bind to NKG2D and increase NK cell activity-
dc.title.alternativeSARS-CoV-2 peptides bind to NKG2D and increase NK cell activity-
dc.typeArticle-
dc.citation.titleCellular Immunology-
dc.citation.number0-
dc.citation.endPage104454-
dc.citation.startPage104454-
dc.citation.volume371-
dc.contributor.affiliatedAuthorHanna Kim-
dc.contributor.affiliatedAuthorByun Jae Eun-
dc.contributor.affiliatedAuthorSuk Ran Yoon-
dc.contributor.affiliatedAuthorHaiyoung Jung-
dc.contributor.affiliatedAuthorIn Pyo Choi-
dc.contributor.alternativeName김한나-
dc.contributor.alternativeName변재은-
dc.contributor.alternativeName윤석란-
dc.contributor.alternativeNameKoohy-
dc.contributor.alternativeName정해용-
dc.contributor.alternativeName최인표-
dc.identifier.bibliographicCitationCellular Immunology, vol. 371, pp. 104454-104454-
dc.identifier.doi10.1016/j.cellimm.2021.104454-
dc.subject.keywordSARS-Cov-2-
dc.subject.keywordNK-
dc.subject.keywordNKG2D-
dc.subject.keywordPeptide-
dc.subject.keywordCytotoxicity-
dc.subject.keywordIFN-γ-
dc.subject.localSARS-CoV-2-
dc.subject.localSARS-Cov-2-
dc.subject.localNK-
dc.subject.localNKG2D-
dc.subject.localpeptide-
dc.subject.localPeptides-
dc.subject.localPeptide-
dc.subject.localCytotoxicity-
dc.subject.localcytotoxicity-
dc.subject.localIFN-γ-
dc.subject.localIfn-γ-
dc.subject.localIFN-gamma-
dc.description.journalClassY-
Appears in Collections:
Aging Convergence Research Center > 1. Journal Articles
Division of A.I. & Biomedical Research > Immunotherapy Research Center > 1. Journal Articles
Files in This Item:
  • There are no files associated with this item.


Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.